In line with routine clinical practice patients wishing to seek a second opinion will be supported to do so. In the first instance clinicians should refer patients for a second opinion using their established protocols. If it is not possible to obtain a second or further opinion using established protocols then National Health Service trusts are instructed to contact their NHS England Regional Medical Director who will be able to offer further advice around a referral route. The NHS England Regional Medical Directors will support NHS trusts in identifying a suitable NHS specialist for a second opinion. Processes may differ in Scotland, Wales and Northern Ireland.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-27T12:42:09.417Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether patients whose prescription for a cannabis-based medical product is blocked by an NHS trust can appeal that decision.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"} } , "tablingMemberConstituency" : {"_value" : "Gower"} , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"} ], "uin" : "266861"} , {"_about" : "http://data.parliament.uk/resources/1133167", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1133167/answer", "answerText" : {"_value" : "
The Department is in regular contact with the National Institute for Health and Care Excellence (NICE) and NHS England colleagues about a range of issues and has not met with drug manufacturers on funding of licensed cannabis-based products.<\/p>
Sativex is currently the only licensed cannabis-based product available in the United Kingdom. NICE considered the clinical and cost effectiveness of Sativex in the development of its clinical guideline on the management of multiple sclerosis published in 2014. NICE was not able to recommend Sativex as a cost-effective use of NHS resources for the treatment of spasticity in people with multiple sclerosis. Sativex is not therefore routinely funded by the NHS in England for use in the treatment of multiple sclerosis, although clinicians are able to make a request for exceptional funding for individual patients who they think may benefit from treatment.<\/p>
NICE has been asked to develop clinical guidelines on cannabis-based products for medicinal use and is expected to look at the clinical and cost effectiveness of treatments, including Sativex, as part of this work. This is expected to be published by October 2019.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-27T12:43:17.543Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent discussions his Department has had with (a) NHS England, (b) drug manufacturers and (c) the National Institute for Health and Care Excellence on funding for licensed cannabis-based products.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4623", "label" : {"_value" : "Biography information for Tonia Antoniazzi"} } , "tablingMemberConstituency" : {"_value" : "Gower"} , "tablingMemberPrinted" : [{"_value" : "Tonia Antoniazzi"} ], "uin" : "266862"} , {"_about" : "http://data.parliament.uk/resources/1133326", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1133326/answer", "answerText" : {"_value" : "
The law stipulates that any doctor on the General Medical Council\u2019s Specialist Register can prescribe cannabis-based products for medicinal use. No licences are required to prescribe.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-06-27", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-27T12:40:10.313Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-06-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Cannabis: Medical Treatments"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many licences have been issued for the prescription of medicinal cannabis.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3936", "label" : {"_value" : "Biography information for Andrew Griffiths"} } , "tablingMemberConstituency" : {"_value" : "Burton"} , "tablingMemberPrinted" : [{"_value" : "Andrew Griffiths"} ], "uin" : "266815"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 3, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }